Kai Yu

Kai Yu

Auto-generated profile, based on publicly available information

Kai Yu

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2026 in Science
Verified
Journal Article
Closed access
KCKyung Serk Cho
Kyung Serk Cho
YLYunhe Liu
Yunhe Liu
GPGuangsheng Pei
Guangsheng Pei
JCJianfeng Chen
Jianfeng Chen
YDYibo Dai
Yibo Dai
LWLinghua Wang
Linghua Wang
Tertiary lymphoid structures (TLSs) are critical regulators of antitumor immunity, yet their spatial organization, maturation, and clinical relevance remain incompletely defined across cancers. We analyzed spatial transcriptomics spanning 12 cancer types to construct a pan-cancer TLS atlas and characterized TLS spatial architecture and maturation states. TLS maturation was accompanied by coordinated remodeling of distinct niche cell populations and distance-dependent gradients in tumor programs, orthogonally supported by ultrahigh-plex single-cell spatial profiling. To enable scalable TLS profiling, we trained an artificial intelligence framework that predicts TLS maturation states directly from hematoxylin and eosin–stained images and evaluated it across TCGA and independent therapy cohorts. We further derived a maturation-aware composite score capturing intratumoral TLS state composition, which robustly stratifies patients across cancer and treatment contexts, outperforming conventional TLS metrics.

13 May 2026 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KYKai Yu
Kai Yu
JCJianfeng Chen
Jianfeng Chen
YCYu-Yi Chu
Yu-Yi Chu
SNSajith Nair
Sajith Nair
ECEmanuele Crupi
Emanuele Crupi
LWLinghua Wang
Linghua Wang
Muscle-invasive bladder cancer (MIBC) is clinically heterogeneous, and current molecular subtyping does not capture the spatial organization of tumor states and microenvironmental context. Here, we construct a spatial atlas of MIBC by integrating spatial transcriptomics from 22 tumors with matched bulk RNA and whole-exome sequencing data. We identify a continuous, spatially organized luminal-to-basal axis within individual tumors that is associated with greater chromosomal instability and transcriptional plasticity. Luminal tumor cores are enriched for FGFR3 and NECTIN4, whereas basal-like states localize toward invasive margins and are associated with elevated EGFR signaling, epithelial–mesenchymal transition, genomic instability, immune infiltration, and greater chemotherapy sensitivity. Spatial analyses further reveal lineage- and location-associated differences in tertiary lymphoid structure states. Pan-cohort analyses across over 3,000 tumors confirm conserved FGFR3–EGFR lineage exclusivity and associated immune programs. Together, these findings define a spatial framework for understanding lineage states, immune architecture, and therapeutic vulnerabilities in MIBC.

20 April 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
KYKai Yu
Kai Yu
RTRebecca Suzanne Slack Tidwell
Rebecca Suzanne Slack Tidwell
TBTharakeswara K Bathala
Tharakeswara K Bathala
RSRahul Sheth
Rahul Sheth
MKMenuka Karki
Menuka Karki
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an aggressive kidney cancer lacking mechanism-directed therapies. We conducted a single-center, single-arm, phase II study (NCT03587662) testing the proteasome inhibitor ixazomib combined with gemcitabine and doxorubicin. Patients and Methods: Ixazomib 5.5 mg, gemcitabine 756 mg/m2, and doxorubicin 42 mg/m2 were given every 2 weeks for up to 13 cycles, followed by ixazomib plus gemcitabine maintenance. Coprimary endpoints were objective response rate (ORR) and 28-week disease-control rate (DCR) versus historic gemcitabine plus doxorubicin. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: Thirty patients (median age 34.5 years old, 90% Black) were treated. The posterior ORR was 36% [95% credible interval (CrI), 21%–54%] with a 91.4% probability of exceeding historic doublet therapy. However, the 28-week DCR was 17% (95% CrI, 6%–31%), crossing the predefined futility boundary. Median PFS and OS were 3.5 and 7.4 months, respectively. Grade ≥3 toxicities were predominantly hematologic (thrombocytopenia 20%, leukopenia 17%) and manageable, with no treatment-related deaths. Single-cell and bulk multi-omics from 11 patients revealed that immune-inflamed tumors enriched for T cells and plasmacytoid/conventional dendritic cells correlated with response, whereas stromal–myeloid niches and proliferative or neuroendocrine–squamous plastic epithelial states associated with resistance. Resistant tumors upregulated unfolded protein response, proteostasis maintenance, and NF-κB pathways. Conclusions: Addition of ixazomib to gemcitabine plus doxorubicin modestly increased radiographic response but did not extend disease control in an all-comer biomarker-unstratified RMC cohort. The integrated correlatives nominate mechanisms and biomarkers to guide future mechanism–directed trials in RMC.

17 June 2026
Verified
Other
Open access
KYKai Yu
Kai Yu
RTRebecca Suzanne Slack Tidwell
Rebecca Suzanne Slack Tidwell
TBTharakeswara K. Bathala
Tharakeswara K. Bathala
RSRahul Sheth
Rahul Sheth
MKMenuka Karki
Menuka Karki
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
Treatment emergent adverse events at least possibly related to study therapy.

17 June 2026
Verified
Other
Open access
KYKai Yu
Kai Yu
RTRebecca Suzanne Slack Tidwell
Rebecca Suzanne Slack Tidwell
TBTharakeswara K. Bathala
Tharakeswara K. Bathala
RSRahul Sheth
Rahul Sheth
MKMenuka Karki
Menuka Karki
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
Stopping criteria for trial-limiting toxicities.

17 June 2026
Verified
Other
Open access
KYKai Yu
Kai Yu
RTRebecca Suzanne Slack Tidwell
Rebecca Suzanne Slack Tidwell
TBTharakeswara K. Bathala
Tharakeswara K. Bathala
RSRahul Sheth
Rahul Sheth
MKMenuka Karki
Menuka Karki
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
Duration of response in patients treated with ixazomib plus gemcitabine plus doxorubicin.